Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimavanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 20/20 | 0.90 |
| ▸ | HTR2C | P28335 | 4/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.90 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.90 |
| ▸ | DRD1 | P21728 | 1/20 | 0.90 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.90 |
| ▸ | GPR183 | P32249 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.90 |
| ▸ | APLNR | P35414 | 1/20 | 0.90 |
| ▸ | DRD3 | P35462 | 1/20 | 0.90 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.90 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.90 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.90 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimavanserin SCHEMBL29384707 | 1.00 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL19975532 | 1.00 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Cadaverine Tartrate SCHEMBL27703324 | 1.00 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| SCHEMBL5503797 | 0.95 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL675165 | 0.95 | HTR2A (1.00) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL970683 | 0.92 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Succinic Acid SCHEMBL28763260 | 0.92 | HTR2A (0.91) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Malic Acid SCHEMBL27676487 | 0.92 | HTR2A (0.84) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL970775 | 0.92 | HTR2A (0.84) | HTR2AHTR2CABCB11CYP1A2ADRB2 | |
| Pimavanserin SCHEMBL969828 | 0.92 | HTR2A (0.90) | HTR2AHTR2CABCB11CYP1A2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084935-A1 | NOVEL POLYMORPH OF PIMAVANSERIN TARTRATE AND PREPARATION METHOD THEREOF AND USE OF SAME | SHANGHAI BEGREAT PHARMATECH (CN) | 2019-03-21 | — | — | US | claimed |
| US-8236960-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. (US) | 2012-08-07 | — | — | US | claimed |
| US-20110184179-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms | ACADIA PHARMACEUTICALS INC. | 2011-07-28 | — | — | US | claimed |
| US-7923564-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | claimed |
| EP-2289879-A1 | Synthesis of a crytalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt | Acadia Pharmaceuticals Inc. (US) | 2011-03-02 | — | — | EP | claimed |
| US-20100305329-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms | ACADIA PHARMACEUTICALS INC. | 2010-12-02 | — | — | US | claimed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | claimed |
| US-7732615-B2 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-2146960-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | claimed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | claimed |
| EP-1794126-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060205781-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | THYGESEN MIKKEL B | 2006-09-14 | — | — | US | claimed |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. | 2006-05-18 | — | — | US | claimed |
| WO-2006037043-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | claimed |
| CN-106518751-B | Method for preparing pimavanserin | 江苏先声药业有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20190084935-A1 | NOVEL POLYMORPH OF PIMAVANSERIN TARTRATE AND PREPARATION METHOD THEREOF AND USE OF SAME | SHANGHAI BEGREAT PHARMATECH (CN) | 2019-03-21 | — | — | US | disclosed |
| US-20060205781-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | THYGESEN MIKKEL B | 2006-09-14 | — | — | US | disclosed |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. | 2006-05-18 | — | — | US | disclosed |
| WO-2006037043-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084935-A1 | NOVEL POLYMORPH OF PIMAVANSERIN TARTRATE AND PREPARATION METHOD THEREOF AND USE OF SAME | PIM1, CYP4F11, CYP4A11 | HTR2A 3398/4885HTR2C 2777/4885ABCB11 1082/4885 |
| US-20060205781-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | MTAP, CPN1, DNPEP | HTR2A 1595/4885HTR2C 1491/4885ABCB11 3685/4885 |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
| US-20100305329-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
| US-20110184179-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885HTR2C 1856/4885ABCB11 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.